Opportunity Information: Apply for PAR 11 100
Apply for PAR 11 100
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Alzheimers Disease Pilot Clinical Trials (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Jan 14, 2011 and posted on Jan 14, 2011.
- Applicants must submit their applications by Jan 7, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Special district governments Native American tribal organizations (other than Federally recognized tribal governments) State governments County governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Independent school districts Native American tribal governments (Federally recognized) Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Alzheimers Disease Pilot Clinical Trials (R01) opportunity (Funding Opportunity Number PAR-11-100) was a National Institutes of Health (NIH) discretionary grant announcement led by the National Institute on Aging (NIA), developed in coordination with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR). It sits within the broader Alzheimers Disease Prevention Initiative that Congress directed NIH to pursue beginning in 1999. That initiative spans basic, epidemiological, behavioral, and clinical research, but this specific announcement is aimed squarely at accelerating the step from promising research findings into early, real-world testing in people through pilot clinical trials.
The central purpose of the FOA was to support pilot (early-stage, exploratory) clinical trials that evaluate interventions intended to prevent or treat cognitive and behavioral symptoms associated with mild cognitive impairment (MCI), Alzheimers disease (AD), and age-related cognitive decline. The scope explicitly included both pharmacologic approaches (for example, drugs or other biologically active agents) and behavioral interventions (for example, structured cognitive, lifestyle, or caregiving-related strategies), as long as the work was framed as a clinical trial and focused on outcomes relevant to cognition and behavior. The announcement also clarifies that while this FOA emphasizes pilot clinical trials, other NIH announcements in the same overall program landscape were oriented toward earlier pipeline activities like drug discovery and development, reinforcing that PAR-11-100 was designed for testing interventions in clinical settings rather than discovering new compounds from scratch.
From an administrative standpoint, the funding mechanism was the NIH R01 research project grant, a standard and widely used mechanism for investigator-initiated research. The funding activity category was listed under Education/Health, and the CFDA number provided was 93.361 (Nursing Research), reflecting participating institute interests that include nursing-relevant research questions and care-focused intervention strategies alongside biomedical approaches. Cost sharing or matching was not required, which is typical for many NIH research grants and reduces barriers for applicants that do not have discretionary funds to contribute.
Eligibility was intentionally broad and included a wide range of organization types across the public, private, nonprofit, and academic sectors. Eligible applicants included small businesses; for-profit organizations (including those other than small businesses); nonprofits with and without 501(c)(3) status; public and private institutions of higher education; and multiple layers of government entities such as state, county, city/township, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The eligibility language also explicitly included organizations and institutions that NIH commonly highlights for inclusion and capacity building, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. In addition, the announcement allowed participation by non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions, indicating an openness to international collaboration and research settings when justified by the scientific aims.
The posting date and creation date were January 14, 2011, with an original closing date of January 7, 2014, and the same listed as the current closing date, after which the opportunity was archived on February 7, 2014. Applicants seeking the full text were directed to the NIH Grants Guide page for PAR-11-100, and technical issues were routed to the NIH Office of Extramural Research (OER) webmaster contact. Overall, the opportunity was designed to speed up the translation of AD-related science into practical, testable prevention and treatment strategies by funding well-justified pilot clinical trials that could generate the evidence needed to move toward larger, definitive studies.
FAQs: Alzheimers Disease Pilot Clinical Trials (R01) - PAR-11-100
What is the Alzheimers Disease Pilot Clinical Trials (R01) opportunity (PAR-11-100)?
PAR-11-100 was a National Institutes of Health (NIH) discretionary funding opportunity announcement for R01 research project grants focused on pilot (early-stage, exploratory) clinical trials in Alzheimers-related research.
Which NIH institute led this funding opportunity?
The National Institute on Aging (NIA) led the announcement.
Which other NIH institutes were involved in developing the announcement?
The opportunity was developed in coordination with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR).
How does PAR-11-100 relate to the Alzheimers Disease Prevention Initiative?
PAR-11-100 sits within the broader Alzheimers Disease Prevention Initiative that Congress directed NIH to pursue beginning in 1999. While the initiative spans basic, epidemiological, behavioral, and clinical research, this specific announcement focused on moving promising findings into early testing in people through pilot clinical trials.
What was the main purpose of this FOA?
The central purpose was to support pilot clinical trials evaluating interventions intended to prevent or treat cognitive and behavioral symptoms associated with mild cognitive impairment (MCI), Alzheimers disease (AD), and age-related cognitive decline.
What types of interventions were in scope?
The scope included both pharmacologic interventions (such as drugs or other biologically active agents) and behavioral interventions (such as structured cognitive, lifestyle, or caregiving-related strategies), as long as the project was framed as a clinical trial and focused on cognition- and behavior-relevant outcomes.
Did this FOA support early discovery work like identifying new compounds?
This announcement emphasized pilot clinical trials rather than earlier pipeline activities like drug discovery and development. It was designed for testing interventions in clinical settings rather than discovering new compounds from scratch.
What funding mechanism did PAR-11-100 use?
The funding mechanism was the NIH R01 research project grant, a standard mechanism for investigator-initiated research.
What was the activity category listed for this opportunity?
The activity category was listed under Education/Health.
What CFDA number was associated with this opportunity?
The CFDA number provided was 93.361 (Nursing Research).
Was cost sharing or matching required?
No. Cost sharing or matching was not required.
What kinds of organizations were eligible to apply?
Eligibility was broad and included organizations across public, private, nonprofit, and academic sectors. Eligible applicants included small businesses; for-profit organizations (including those other than small businesses); nonprofits with and without 501(c)(3) status; and public and private institutions of higher education.
Were government entities eligible, and if so which types?
Yes. Eligible government entities included state, county, city/township, and special district governments, as well as independent school districts and public housing authorities/Indian housing authorities.
Were HBCUs and other minority-serving institutions explicitly included in eligibility?
Yes. The eligibility language explicitly included Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and other groups NIH commonly highlights for inclusion and capacity building.
Could faith-based or community-based organizations apply?
Yes. Faith-based and community-based organizations were explicitly included in the eligibility language.
Were non-U.S. (foreign) organizations allowed to participate?
Yes. The announcement allowed participation by non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions.
What conditions or research focus did projects need to address?
Projects needed to focus on interventions relevant to mild cognitive impairment (MCI), Alzheimers disease (AD), and/or age-related cognitive decline, with outcomes tied to cognitive and behavioral symptoms, and the work needed to be structured as a pilot clinical trial.
When was the opportunity posted?
The posting date (and creation date) was January 14, 2011.
What was the closing date for applications?
The original closing date was January 7, 2014, and the same date was listed as the current closing date.
Is this funding opportunity still open?
No. The opportunity was archived on February 7, 2014, after the January 7, 2014 closing date.
Where were applicants directed to find the full text of the announcement?
Applicants were directed to the NIH Grants Guide page for PAR-11-100.
Where were technical issues directed?
Technical issues were routed to the NIH Office of Extramural Research (OER) webmaster contact.
What was the overall goal of funding these pilot clinical trials?
The overall goal was to speed the translation of Alzheimers-related research into practical, testable prevention and treatment strategies by supporting well-justified pilot clinical trials that could generate evidence needed to move toward larger, definitive studies.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: U.S. India Bilateral Brain Research Collaborative Partnerships (U.S. India BRCP) (R21)
Previous opportunity: Special Research Grants Program Potato Breeding Research
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 100
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 100) also looked into and applied for these:
| Funding Opportunity |
|---|
| U.S. India Bilateral Brain Research Collaborative Partnerships (U.S. India BRCP) (R21) Apply for PAR 11 099 Funding Number: PAR 11 099 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Increasing Opportunities in Advanced Heart Failure and Palliative Care Research (R01) Apply for RFA NR 11 006 Funding Number: RFA NR 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R01) Apply for PA 11 104 Funding Number: PA 11 104 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Reducing Health Disparities Among Minority and Underserved Children (R21) Apply for PA 11 105 Funding Number: PA 11 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Lasker Clinical Research Scholars Program (SI2) Apply for RFA OD 11 001 Funding Number: RFA OD 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 11 102 Funding Number: PAR 11 102 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 11 009 Funding Number: RFA DA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 11 002 Funding Number: RFA CA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Predictive Animal Models for Smoking Cessation Medications (U54) Apply for RFA DA 11 014 Funding Number: RFA DA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 11 108 Funding Number: PAR 11 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Related Disorders (U01) Apply for PAR 11 109 Funding Number: PAR 11 109 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 11 111 Funding Number: PA 11 111 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows In Nursing Research (F31) Apply for PAR 11 117 Funding Number: PAR 11 117 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U42) Apply for PAR 11 116 Funding Number: PAR 11 116 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U24) Apply for PAR 11 115 Funding Number: PAR 11 115 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS Implementation Science Targeting Drug Using Populations A Collaboration with PEPFAR (R01) Apply for RFA DA 12 002 Funding Number: RFA DA 12 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Placebo Effect Mechanisms and Methodology (R21) Apply for RFA DA 12 004 Funding Number: RFA DA 12 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Placebo Effect Mechanisms and Methodology (R01) Apply for RFA DA 12 003 Funding Number: RFA DA 12 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Childhood Cancer Survivor Study (CCSS)(Limited Competition U24) Apply for RFA CA 11 501 Funding Number: RFA CA 11 501 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medication Initiative for Tobacco Dependence (MITD) A New Product Development Partnership (PDP)(UH2/UH3) Apply for RFA DA 11 015 Funding Number: RFA DA 11 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 100", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.